An FLT3 mutation test checks acute myeloid leukemia (AML) cells for activating changes in the FLT3 gene, most commonly an internal tandem duplication (FLT3-ITD) or a tyrosine kinase domain mutation (FLT3-TKD). The result matters quickly because FLT3 is both a disease-risk marker and a treatment-selection biomarker. FLT3-ITD has historically been linked to higher relapse risk, while modern FLT3 inhibitors have improved outcomes and changed how the mutation is used in current risk systems. The test is usually performed on bone marrow or peripheral blood at AML diagnosis and should often be repeated if the leukemia relapses because FLT3 status can change over time. A positive report should be read beyond the word “detected”: the mutation subtype, assay method, co-mutations such as NPM1, and the treatment setting all affect its meaning. Older reports may also include an FLT3-ITD allelic ratio, but ELN 2022 no longer uses that ratio to assign genetic risk.
- FLT3-ITD and FLT3-TKD are the main mutation types; together they occur in roughly one-quarter to one-third of AML cases.
- FLT3-ITD is clinically important for relapse risk and can qualify adults with newly diagnosed AML for FLT3-directed treatment, depending on the regimen and drug label.
- ELN 2022 places FLT3-ITD AML in the intermediate-risk group unless another genetic feature independently changes the category; the old high-versus-low allelic-ratio rule was removed.
- A negative FLT3 result does not rule out AML and may need to be repeated at relapse because a previously absent or present FLT3 clone can change.
- Testing is urgent at diagnosis because the result can affect frontline treatment; no fasting or special preparation is required for the molecular assay itself.
Table of Contents
- What FLT3 Testing Measures
- How FLT3 Mutation Testing Is Done
- How to Read a Positive or Negative Result
- FLT3-ITD Risk and the ELN 2022 Change
- How FLT3 Results Guide Treatment
- Allelic Ratio, VAF, and MRD
- When to Repeat Testing and What Happens Next
What FLT3 Testing Measures
FLT3 testing looks for activating mutations in a receptor tyrosine kinase that helps regulate normal blood-cell growth. When FLT3 is mutated in an AML cell, the receptor can signal continuously without the normal growth control. That persistent signaling promotes proliferation and survival of the leukemic clone.
The two main mutation groups are FLT3-ITD and FLT3-TKD.
FLT3-ITD means internal tandem duplication. A stretch of DNA in the juxtamembrane region, and sometimes nearby regions, is duplicated and inserted back into the gene. ITDs vary greatly in length and exact location. They are found in about 20% of AML overall in large pooled analyses, although frequency differs by age and AML subtype.
FLT3-TKD refers mainly to activating point mutations in the tyrosine kinase domain, especially at D835 and nearby residues such as I836. TKD mutations are less common, often around 5–10% of AML. Their prognostic effect is less uniform than that of FLT3-ITD and depends heavily on co-mutations and treatment.
The test is usually part of the initial AML molecular workup because modern management requires a rapid profile of actionable and risk-defining abnormalities. Other commonly tested genes include NPM1, IDH1, IDH2, TP53, CEBPA, and genes associated with myelodysplasia-related AML. An NPM1 mutation result is particularly important when interpreting FLT3 because NPM1 and FLT3-ITD often occur together and current risk classification considers the full combination.
FLT3 is not itself required to diagnose AML. Some AML entities are defined by other genetic changes, and many patients are FLT3 wild type. The value of FLT3 testing is mainly predictive, prognostic, and increasingly useful for measurable residual disease in selected settings.
How FLT3 Mutation Testing Is Done
FLT3 testing can use polymerase chain reaction with capillary electrophoresis, next-generation sequencing, or both. The ideal assay must detect variable-length ITDs as well as clinically relevant TKD mutations with enough sensitivity for the intended use.
Traditional PCR and fragment analysis is particularly well established for FLT3-ITD. The laboratory amplifies the FLT3 region and measures DNA fragment sizes. A duplicated segment produces an abnormal longer fragment. Targeted PCR methods can also detect common TKD mutations.
NGS can evaluate FLT3 alongside dozens or hundreds of other genes. Modern assays and bioinformatics pipelines can detect ITDs, but large or structurally complex ITDs can be technically challenging for some sequencing systems. A laboratory should validate its ability to detect the clinically relevant spectrum rather than assuming every generic NGS panel performs identically.
The specimen is usually bone marrow aspirate or peripheral blood. Bone marrow is common at diagnosis because it is already being obtained for blast count, morphology, flow cytometry, chromosome analysis, and molecular testing. Peripheral blood can work well when sufficient leukemia cells are circulating.
A report may include:
| Report item | Typical information | Why it matters |
|---|---|---|
| FLT3-ITD | Detected or not detected | Identifies the major prognostic and treatment-relevant FLT3 subtype |
| FLT3-TKD | Detected or not detected, often with exact variant | Can support use of FLT3-directed therapy depending on setting |
| Allelic ratio or mutant signal | Sometimes reported with ITD assays | Historically used for risk; no longer part of ELN 2022 risk assignment |
| VAF | Often reported by NGS | Estimates the proportion of sequence reads carrying the variant |
| Assay sensitivity | Laboratory-specific limit of detection | Important when comparing diagnostic and MRD assays |
No fasting is needed. The practical issue is turnaround time. FLT3 results are often prioritized because treatment can begin quickly after AML diagnosis and the result may affect the induction regimen. The exact turnaround varies by laboratory and institution.
Sample quality can influence sensitivity. A blood specimen with very few circulating blasts may contain less leukemic DNA than the bone marrow, while a marrow aspirate diluted with peripheral blood can also reduce tumor content. If the clinical suspicion is high and a negative result came from a low-blast specimen, the laboratory or treating team may prefer a better sample rather than assuming FLT3 is truly absent.
FLT3-ITD also creates a special technical challenge because every patient’s duplication can be a different length and sequence. PCR fragment analysis detects the size difference directly and remains a robust diagnostic method. NGS provides richer sequence information and can report the exact ITD, but the sequencing chemistry and software must be designed to identify insertions that may be longer than a standard read. This is one reason laboratories sometimes use a rapid FLT3-specific assay alongside a broader NGS panel.
A result can also differ between specimens taken days apart if leukemia burden changes rapidly or treatment has already begun. When a molecular result will determine eligibility for a targeted drug, clinicians generally rely on a pretreatment or clearly documented diagnostic specimen whenever possible.
How to Read a Positive or Negative Result
A positive FLT3 result means an activating FLT3 mutation was detected in the tested leukemia sample. The first question should be whether it is ITD, TKD, or both.
An FLT3-ITD-positive report supports a molecular subtype associated with increased proliferative signaling and, historically, a greater relapse tendency. Before FLT3 inhibitors became routine, ITD positivity often carried a distinctly unfavorable outlook. Today, prognosis is more treatment-dependent because targeted therapy, transplant strategies, and MRD assessment can substantially change outcomes.
A TKD-positive report commonly identifies a mutation involving D835 or I836, although other activating variants occur. TKD mutations do not have one simple, universal risk meaning. They can be primary AML mutations or emerge as resistance mutations during treatment with certain FLT3 inhibitors.
A negative result means no reportable FLT3 mutation was found above the assay’s detection limit in that specimen. It does not mean the leukemia is low risk, and it does not exclude AML. Other mutations, chromosome abnormalities, MRD response, age, and disease biology may be more important.
Co-mutations matter. NPM1-mutated AML frequently carries FLT3-ITD. DNMT3A can also coexist with NPM1 and FLT3. A broad molecular report may therefore contain several findings that seem to point in different directions. Risk is assigned using the highest-priority defining genetic features in the current classification, not by averaging individual gene labels.
The exact ITD size, insertion site, and mutant burden have been studied as prognostic variables. These details can be biologically meaningful, but routine treatment decisions are not based on one universally accepted ITD-length or insertion-site threshold.
If a report says “FLT3 mutation detected” without identifying the type, ask for the full molecular interpretation. ITD and TKD have different treatment labels and different roles in risk and resistance.
FLT3-ITD Risk and the ELN 2022 Change
The 2022 European LeukemiaNet recommendations made an important change: FLT3-ITD allelic ratio is no longer used to divide AML into favorable and intermediate risk. In ELN 2017, the relationship between NPM1 mutation and a high or low FLT3-ITD allelic ratio affected risk assignment. That approach was removed because the assay was difficult to standardize across laboratories and because routine FLT3-inhibitor therapy altered the prognostic landscape.
Under ELN 2022, AML with FLT3-ITD is generally placed in the intermediate-risk category, regardless of allelic ratio and regardless of whether NPM1 is also mutated, unless another adverse-risk genetic feature changes the classification.
This creates a practical difference between two NPM1-mutated cases. NPM1-mutated AML without FLT3-ITD can qualify as favorable risk when adverse-risk cytogenetic abnormalities are absent. If FLT3-ITD is also present, the case moves to intermediate risk under the ELN 2022 genetic framework.
The intermediate label does not mean every FLT3-ITD patient has the same prognosis. Outcomes differ according to age, co-mutations, white blood cell count, response depth, transplant eligibility, FLT3 inhibitor exposure, and post-treatment MRD. A risk category is a population-based framework for planning care, not a prediction of an individual survival time.
A dedicated TP53 mutation result or an adverse-risk chromosome abnormality can outweigh the implications of FLT3 and place the overall AML in a higher-risk group.
The key takeaway is that old internet explanations based on “low FLT3 ratio plus NPM1 equals favorable” can be outdated. A current interpretation should state which risk system is being used and whether it reflects the ELN 2022 framework.
How FLT3 Results Guide Treatment
FLT3 is one of the clearest examples of a predictive biomarker in AML because the mutation can identify patients for FLT3-targeted drugs.
For adults with newly diagnosed FLT3-mutated AML who receive intensive induction chemotherapy, midostaurin is an established FLT3 inhibitor used with standard induction and consolidation in appropriate patients. Its companion diagnostic recognizes both ITD and common TKD mutations.
For adults with newly diagnosed FLT3-ITD-positive AML, quizartinib is FDA approved with standard cytarabine/anthracycline induction and cytarabine consolidation, followed by maintenance after consolidation in the approved setting. The pivotal QuANTUM-First trial showed an overall-survival benefit from adding quizartinib to intensive chemotherapy for FLT3-ITD-positive AML.
For adults with relapsed or refractory FLT3-mutated AML, gilteritinib is an established targeted treatment. This is one reason retesting at relapse matters: the leukemia may gain or lose FLT3 mutations between diagnosis and recurrence.
Treatment is more complex for older adults or people not receiving intensive chemotherapy. Combinations involving hypomethylating agents, venetoclax, and FLT3 inhibitors are an active and evolving area. The appropriate regimen depends on current approvals, guidelines, prior therapy, patient fitness, transplant plans, and clinical-trial availability.
A positive FLT3 result also influences transplant discussions in many patients. Allogeneic hematopoietic cell transplantation may be considered in first remission for selected intermediate-risk FLT3-ITD AML, especially when relapse risk remains high. MRD status before transplant can add important prognostic information.
The molecular test does not prescribe a drug by itself. Clinicians must account for cardiac risk, QT-prolonging medications, drug interactions, organ function, prior therapy, and the exact FLT3 subtype when choosing an inhibitor.
Allelic Ratio, VAF, and MRD
Two numbers can appear on FLT3 reports: allelic ratio and variant allele frequency (VAF). They are related concepts but are not interchangeable.
An ITD allelic ratio from fragment analysis generally compares the mutant FLT3 signal with the wild-type signal. VAF from NGS is the proportion of sequencing reads carrying the mutation. Differences in sample purity, blast percentage, copy number, assay design, and bioinformatics can make these values diverge.
Because there is no universally standardized conversion, a 0.5 allelic ratio should not simply be translated into “50% VAF.” Likewise, numbers from different laboratories should not be compared without knowing the methods.
For measurable residual disease (MRD), the assay must be much more sensitive than a routine diagnostic test. A standard NGS panel designed to detect variants at 2–5% VAF can be perfectly adequate for diagnosis but too insensitive to exclude residual leukemia at levels of 0.1%, 0.01%, or lower.
FLT3-ITD was once considered a difficult standalone MRD marker because the clone can change over time. More sensitive error-corrected sequencing has improved its usefulness. The 2025 ELN-DAVID MRD update specifically supports ultrahigh-sensitivity NGS-based FLT3-ITD assessment after intensive chemotherapy and before allogeneic transplantation in appropriate FLT3-ITD AML.
MRD interpretation should still be integrated with other markers. If AML also has NPM1 mutation, a highly sensitive AML MRD strategy may combine NPM1 molecular testing with flow cytometry and, increasingly, sensitive FLT3-ITD sequencing.
A falling FLT3 burden during therapy is generally encouraging, but the clinically relevant question is whether validated MRD thresholds and time points have been met—not simply whether the diagnostic VAF became smaller.
When to Repeat Testing and What Happens Next
FLT3 should be tested at AML diagnosis and is commonly retested at relapse or progression. Leukemia is genetically dynamic. An FLT3-mutated clone can disappear under treatment, while a previously small or undetectable FLT3 clone can become dominant later. Treatment with a FLT3 inhibitor can also select resistance mutations.
After a new diagnosis, the care team combines FLT3 with the rest of the molecular panel, chromosome studies, morphology, immunophenotype, patient age and health, and treatment goals. If the result is pending but intensive therapy needs to begin, the institution may use a rapid FLT3 assay so targeted therapy can be added on schedule.
During remission, testing depends on the molecular profile. Routine diagnostic-level sequencing is not automatically an MRD test. If FLT3-ITD will be used for MRD, the laboratory should use a validated high-sensitivity method and report the appropriate threshold.
At relapse, repeat testing may change treatment eligibility. A patient who was FLT3 negative at diagnosis can become FLT3 positive at recurrence, and a previously FLT3-positive patient can relapse with a FLT3-negative dominant clone. The current sample is therefore more relevant to current targeted therapy than an old result alone.
Questions worth asking after receiving a report include:
- Is the mutation FLT3-ITD, FLT3-TKD, or both?
- Was the sample blood or bone marrow, and was there enough leukemia in it?
- Which ELN risk category applies after considering all mutations and cytogenetics?
- Does the result qualify for a specific FLT3 inhibitor in this treatment setting?
- Is an MRD-capable assay available for this mutation?
- Will FLT3 be repeated if the disease relapses?
The most accurate interpretation treats FLT3 as a dynamic clinical biomarker rather than a permanent label. Its meaning changes with the mutation subtype, co-mutations, treatment received, and point in the disease course.
References
- Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN 2022 (Guideline)
- FLT3 mutations as diagnostic and prognostic biomarkers in acute myeloid leukemia 2026 (Review)
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial 2023 (RCT)
- Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments 2024 (Review)
- 2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working Party 2026 (Guideline)
- FDA approves quizartinib for newly diagnosed acute myeloid leukemia 2023
Disclaimer
FLT3 results must be interpreted with the complete AML diagnosis, current risk system, co-mutations, treatment history, and assay method. Drug indications and treatment standards can change, and a molecular result alone does not determine the best regimen. Discuss current treatment and MRD implications with a hematologist or leukemia specialist.
